ALTEMO: Effects of Prenatal Alcohol Exposure on Emotional and Cognitive Abilities in Adults

Sponsor
University Hospital, Lille (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT03793920
Collaborator
(none)
144
2
4
48.1
72
1.5

Study Details

Study Description

Brief Summary

Hypothesis:

Individuals presenting with prenatal alcohol exposure (PEA) show emotional abilities deficits, and imbalance between the two systems involved in decision-making according to dual-process models, namely an under-activated reflective system (involved in deliberate behaviors) and an over-activated affective-automatic one (involved in impulsive behaviors).

Primary objective:

To explore performance (as a percentage of correct answers) in an emotional facial expression decoding task in PEA participants compared to controls without alcohol disorder.

Condition or Disease Intervention/Treatment Phase
  • Other: Facial Emotion Test
N/A

Detailed Description

Each participant will undergo 2 visits :
First visit :
  • Checking inclusion and non-inclusion criteria

  • Note of information and consent form

  • Record of concomitant treatments and anamnestic elements

  • Alcohol, Tobacco, and Toxic Consumption

  • Urinary Toxicity Test for Control Groups

  • Laterality test (Hecaen, 1984)

  • Brief visual and auditory acuity test

  • Standardized psychiatric interview (Mini International Neuropsychiatric Interview - MINI)

Second visit = Experimental testing

  • State-Trait Anxiety Inventory, Beck Depression Inventory, Inventory of Interpersonal Problems, Toronto Alexithymia Scale (TAS-20).

  • Participant installation and testing: 6 behavioral tasks on a computer (also used to collect responses, except for task 2, see details below) :

Task 1 (MAIN): Test for recognition of facial emotions Task 2: 'Reading the Mind in the Eyes Test' (Decoding of complex emotional states) Task 3: Emotional evaluation of natural scenes Task 4: Target detection (measure of attentional bias towards alcohol-related stimuli) Task 5: Go / No-Go evaluating the interactions between inhibition processes and auto-affective system Task 6: "N-back" evaluating the interactions between working memory and automatic-affective system

Study Design

Study Type:
Interventional
Anticipated Enrollment :
144 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Behavioral Exploration of Cognitive and Emotional Alterations in Adult Individuals Exposed to Alcohol During the Prenatal Period
Actual Study Start Date :
Nov 8, 2018
Anticipated Primary Completion Date :
Nov 11, 2022
Anticipated Study Completion Date :
Nov 11, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: PEA patients without alcohol disorder

A group of 36 PEA patient without alcohol-dependence (AD), performing 6 behavioral tasks.

Other: Facial Emotion Test
All tasks will be delivered using a laptop and E-Prime 2 software (Psychology Software Tools, Inc., Pittsburgh), which will also be used to collect behavioral responses.

Sham Comparator: PEA patients with alcohol disorder

A group of 36 PEA participants, currently alcohol-dependent, performing 6 behavioral tasks.

Other: Facial Emotion Test
All tasks will be delivered using a laptop and E-Prime 2 software (Psychology Software Tools, Inc., Pittsburgh), which will also be used to collect behavioral responses.

Sham Comparator: Healthy controls with AD father

A group of 36 non-alcohol-dependent controls whose father was alcohol-dependent during their childhood and adolescence, performing 6 behavioral tasks.

Other: Facial Emotion Test
All tasks will be delivered using a laptop and E-Prime 2 software (Psychology Software Tools, Inc., Pittsburgh), which will also be used to collect behavioral responses.

Sham Comparator: Healthy controls without AD father

A group of 36 non-alcohol-dependent controls whose father was not alcohol-dependent during their childhood and adolescence, performing 6 behavioral tasks.

Other: Facial Emotion Test
All tasks will be delivered using a laptop and E-Prime 2 software (Psychology Software Tools, Inc., Pittsburgh), which will also be used to collect behavioral responses.

Outcome Measures

Primary Outcome Measures

  1. Percentage of correct answers of an emotional facial expression (EFE) [one day]

    Performance of an emotional facial expression (EFE) decoding task in EPA subjects and compare it to non-alcohol dependent controls

Secondary Outcome Measures

  1. Psychopathological assessment by Mini International Neuropsychiatric Interview MINI [one day]

    Presence of psychiatric disorders by a standardized psychiatric interview

  2. Percentage of correct answers ant latency of behavioral answers [one day]

    Performance of behavioral tasks

  3. State-Trait-Anxiety Inventory (STAI) score [one day]

    Score at STAI STAI is a psychological inventory based on a 4-point Likert scale and consists of 40 questions on a self-report basis

  4. Beck Depression Inventory score [one day]

    Score at Beck Depression Inventory The BDI consisted of twenty-one questions about how the subject has been feeling in the last week. Each question had a set of at least four possible responses, ranging in intensity. (0) I do not feel sad/ (1) I feel sad./ (2) I am sad all the time and I can't snap out of it/ (3) I am so sad or unhappy that I can't stand it. When the test is scored, a value of 0 to 3 is assigned for each answer and then the total score is compared to a key to determine the depression's severity. The standard cut-off scores were as follows:0-9: indicates minimal depression/ 10-18: indicates mild depression/ 19-29: indicates moderate depression/ 30-63: indicates severe depression.

  5. Toronto Alexithymia Scale TAS-20 score [one day]

    Score at TAS-20 The Toronto Alexithymia Scale is a measure of deficiency in understanding, processing, or describing emotions. The current version has twenty statements rated on a five-point Likert scale. ( range : Strongly disagree/Disagree/ Neither agree nor disagree/ Agree/ Strongly agree)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Man or woman aged between 18 and 60 years

  • Able to understand and to speak French

  • Able to understand Note of information and to sign consent form

  • Available health insurance

  • Normal (or corrected to normal) vision and audition

  • For women: Negative pregnancy test or menopausal for at least one year

  • For Group 1 only : PEA criteria and no alcohol consumption within the three days preceding the experiment.

  • For Group 2 only : PEA criteria, diagnosed with severe alcohol addiction and currently abstinent (for at least 15 days).

  • For Group 3 only : Non-alcohol-dependent controls. No alcohol consumption within the three days preceding the experiment and father diagnosed with severe alcohol addiction.

  • For Group 4 only : Non-alcohol-dependent controls. No alcohol consumption within the three days preceding the experiment.

Exclusion Criteria:
  • Refusal of participation after clear and fair information on the study.

  • Visual or auditory sensory disability to participate in the study.

  • Benzodiazepines and / or Antipsychotic concomitant treatment.

  • History of (or current) neurologic disease

  • History of (or current) psychiatric disorder (apart alcohol-dependence for the PEA-alcohol-dependent group)

  • Psychoactive Substance Use or Abuse other than tobacco and alcohol.

  • Pregnant or breast-feeding women.

  • Underage (<18 yo) or adults under guardianship, judicial protection, or deprived of liberty.

Contacts and Locations

Locations

Site City State Country Postal Code
1 CSAPA Lille France 59037
2 CHRU Lille, Fontan2 Lille France

Sponsors and Collaborators

  • University Hospital, Lille

Investigators

  • Principal Investigator: Olivier COTTENCIN, MD, PhD, University Hospital, Lille

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Lille
ClinicalTrials.gov Identifier:
NCT03793920
Other Study ID Numbers:
  • 2015_76
  • 2017-A00843-50
First Posted:
Jan 4, 2019
Last Update Posted:
Aug 25, 2020
Last Verified:
Aug 1, 2020
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Lille

Study Results

No Results Posted as of Aug 25, 2020